The ACB has played an essential watch-dog role on new GMO permits in South Africa for a decade now, adding substantially to the discourse about the scientific assessment of GMOs as well as about issues of socioeconomic impacts and democratic decisionmaking, through lodging substantive comments on at least 30 permit applications.
On this page you will find all of ACB’s publications. To the right are the search categories that will help you navigate around the ACB’s extensive work.
ACB is objecting to the commodity clearance of the triple-stacked GM soybean event MON 87708 x MON 89788 x A5547-127, due to concerns surrounding the lack of safety assessment data for this crop and the known toxicity of the three pesticides it is designed to tolerate.
The Tanzania National Farmers Network Organisation, Mtandao wa Vikundi vya Wakulima Tanzania (MVIWATA) and the African Centre for Biodiversity (ACB) are objecting to an application submitted by the Tanzania Commission for Science and Technology (COSTECH) for confined field trials of Monsanto’s stacked GM maize MON 87460 X MON 810 (GM drought tol
In this objection, ACB raises numerous concerns with the application by Monsanto for the commercial release of the triple stacked event.
Supported by: More than 25 000 people who signed a Care2 “#VoteNoToGMO!" Petition. We Say No to Monsanto Petition by 25 000 people who signed a Care2 “#VoteNoToGMO!” Petition.
South Africa is in the grip of the worst drought since 1992, with many parts of the country experiencing record temperatures and little to no rain.
The African Centre for Biodiversity (ACB) has on 7th August 2015, lodged an appeal to Agriculture, Water Affairs and Forestry Minister Senzeni Zokwana, against the general release approval of Monsanto’s genetically modified (GM) maize, MON87460 granted by the Executive Council (EC): GMO Act.
This submission by Monsanto makes a joke of biosafety risk assessment in that it is not based on the actual event under consideration, but rather, the applicant posits claim of lack of harm, toxicity, and allergenicity based on data carried out on other lines containing the same transgene/event.